Sling Therapeutics

Sling Therapeutics, Inc. is a biopharmaceutical company focused on developing oral small-molecule drugs for the treatment of Thyroid Eye Disease (TED). The company is advancing the evaluation of its lead candidate, Linsitinib, in a Phase 2b clinical trial based on extensive preclinical and clinical data. Linsitinib is a convenient oral small-molecule drug that can significantly reduce the treatment burden for patients with TED.